HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients

Hepatology International

Volumn 7, Issue 4, 2013, Pages 969-980

  Turyadi, ^a   Thedja, Meta Dewi ^a,b   Ie, Susan Irawati ^a   Harahap, Alida Roswita ^a,c   El Khobar, Korri Elvanita ^a   Roni, Martono ^a   Muljono, David Handojo ^a,d,e  

^a EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d HASANUDDIN UNIVERSITY   (Indonesia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Basal core promoter; Chronic hepatitis B; HBeAg; HBsAg; HBV DNA; Natural history; Precore mutation; Quantitative serology

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ETHNIC GROUP; FEMALE; GENETIC ASSOCIATION; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; INDONESIAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEROCONVERSION; VERY ELDERLY; VIRAL CLEARANCE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 84890559640     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9438-z     Document Type: Article

References (54)

1. World Health Organization (WHO). Hepatitis B Fact Sheet No. 204. 2012. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 18 Sept 2012.
2. Khan M, Dong JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, Jafri SMW, Mulyono DH, Tozun N, Sarin SK. Hepatology issues in Asia: perspectives from regional leaders. J Gastroenterol Hepatol. 2004;19:S419-S430.
3. Lok ASF, McMahon BJ. AASLD practice guideline update: chronic hepatitis B: update 2009. Hepatology. 2009;50(3):1-36.
4. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6(3):531-561 (Erratum in Hepatol Int 2012;6:809-810).
5. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic level and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology. 2006;44:694-702.
6. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48-64.
7. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;28(8):967-975.
8. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-592.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
10. Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ. The association of HBV core promoter double mutations A1762T and G1764A with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J Hepatol. 2009;50:273-280.
11. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181.
12. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246-252.
13. Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology. 2002;295(1):86-96.
14. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2(8663):588-591.
15. Thompson AJV, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GKK, Lewin SR, Visvanathan K, Desmond PV, Locarnini S. Serum hepatitis B surface antigen nd hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933-1944.
16. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of Hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750-1758.
17. Ahn SH, Chan HLY, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386-395.
18. ® HBeAg immunoassay. J Viral Hepat. 2011;18(7):179-183.
19. Tong MJ, Hsu L, Hsien C, Kao JH, Durazo FA, Saab S, Blatt LM. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int. 2010;4:516-522.
20. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat. 2008;15:1-21.
21. Kim YJ, Cho HC, Choi MSS, Lee JH, Koh KC, Yoo BC, Paik SW. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int. 2011;31(6):817-823.
22. Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang. 1992;63:107-111.
23. Okamoto H, Nishizawa T. Non-B Non-C Non-G hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus. 1992. http://www.freepatentsonline.com/EP1010759.html (with permission). Accessed 24 Feb 2010.
24. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, Perez H, Cahn P, Salomon H. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007;23(4):525-531.
25. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyazawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987;61(10):3030-3034.
26. Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol. 1992;73:3141-3145.
27. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68(12):8102-8110.
28. Jaroszewicz J, Serrano BC, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514-522.
29. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010;15(Suppl.3):25-33.
30. Chan HLY, Wong VHS, Wong GLH, Tse CH, Chan HY, Sung JJY. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52:1232-1241.
31. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011;53:2121-2129.
32. Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol. 2011;50(4):292-296.
33. Nguyen T, Thompson AJV, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini S. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508-513.
34. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, Chang MH, Chen DS. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol. 2010;84(7):3454-3463.
35. Stibbe W, Gerlich WH. Structural relationships between minor and major proteins of hepatitis B surface antigen. J Virol. 1983;46(2):626-628.
36. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010;52:475-477.
37. Bill CA, Summers J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc Natl Acad Sci USA. 2004;101(30):11135-11140.
38. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:S5-S15.
39. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat. 2010;17:115-122.
40. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ. Carriers of Inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747-1754.
41. Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of inactive carrier state versus chronic hepatitis. Dig Liver Dis. 2011;43:S8-S14.
42. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-1129.
43. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, Wasser S, Peter FJ, Tan T, Goode M, Rodrigo AG. Viral quasi-species evolution during hepatitis B e antigen seroconversion. Gastroenterology. 2007;133(3):951-958.
44. Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol. 2012;56:795-802.
45. Mulyanto, Tsuda F, Karosi AT, Soewignjo S, Roestamsjah, Sumarsidi D, Trisnamurti RH, Sumardi, Surayah, Udin LZ, Melani-Wikanta, Kanai K, Mishiro S. Distribution of the hepatitis B surface antigen subtypes in Indonesia: implications for ethnic heterogeneity and infection control measures. Arch Virol. 1997;142:2121-2129.
46. Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608-614.
47. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma. Gastroenterology. 2003;124:327-334.
48. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RSJ, Luketic VA. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis. 2002;186:1335-1338.
49. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31(5):1037-1044.
50. Davidson F, Lycett C, Sablon E, Petrik J, Dow BC. Hepatitis B virus genotypes and precore mutations in Scottish blood donors. Vox Sang. 2005;88(2):87-92.
51. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, Chauhan R, Bose S. Virologic and histology features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376-1384.
52. Park JY, Park YN, Kim DY, Paik YH, Lee KS, Moon BS, Han KH, Chon CY, Ahn SH. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high Terrault N, Lok ASF, The US HBV Epidemiology Study Group. Prevalence of HBV Precore/Core Promoter variants in the United States. Hepatology. 2003;38:619-628.
53. Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DKH, Doutreloigne J. Relationship between the development of precore serum HBV DNA levels. J Viral Hepat. 2008;15(8):615-621.
54. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133:843-843.